Compare MHH & INM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MHH | INM |
|---|---|---|
| Founded | 1986 | 1981 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 89.7M | 7.7M |
| IPO Year | 2008 | 2020 |
| Metric | MHH | INM |
|---|---|---|
| Price | $7.43 | $1.30 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 9.1K | ★ 66.3K |
| Earning Date | 05-15-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 62.68 |
| EPS | ★ 0.01 | N/A |
| Revenue | ★ $191,371,000.00 | $4,942,633.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $9.07 | N/A |
| P/E Ratio | $740.00 | ★ N/A |
| Revenue Growth | N/A | ★ 7.50 |
| 52 Week Low | $5.51 | $0.58 |
| 52 Week High | $8.37 | $2.50 |
| Indicator | MHH | INM |
|---|---|---|
| Relative Strength Index (RSI) | 46.47 | 36.87 |
| Support Level | $6.78 | $1.03 |
| Resistance Level | $7.72 | $1.40 |
| Average True Range (ATR) | 0.12 | 0.08 |
| MACD | -0.00 | -0.01 |
| Stochastic Oscillator | 57.14 | 5.97 |
Mastech Digital Inc is a provider of Digital Transformation IT Services. The Company offers data & analytics solutions & IT staffing services for both digital & mainstream technologies. The Group has two segments. Its Data & Analytics Services segment delivers specialized data management, data engineering, customer experience consulting, data analytics & cloud services to customers globally. The IT Staffing Services segment combines technical expertise with business process experience to deliver a broad range of services in digital & mainstream technologies. The company derives a majority of its revenue from IT staffing services. Geographically, the majority of revenue is generated from the United States.
InMed Pharmaceuticals Inc is a pharmaceutical company developing a pipeline of disease-modifying small molecule drug candidates targeting CB1 and CB2 receptors. The company's pipeline consists of three separate programs in the treatment of Alzheimer's, ocular and dermatological indications.